Literature DB >> 21763644

T-cell specific defect in expression of the NTPDase CD39 as a biomarker for lupus.

Matthew J Loza1, A Shane Anderson, Kenneth S O'Rourke, James Wood, Islam U Khan.   

Abstract

Regulatory T cells (T(regs)) are critical for maintenance of peripheral tolerance via suppression of T-cell responses, and absence of T(regs) results in autoimmunity. The role of aberrations in the T(reg) pool for the development of systemic lupus erythematosus (SLE, lupus) remains uncertain. T(reg)-mediated generation of adenosine, dependent on the ectonucleotidase CD39, is an important mechanism for suppression of T-cell responses. We tested whether decreases in numbers of T(regs), and specifically CD39-expressing T(regs), are associated with human lupus. We studied 15 SLE patients, six patients with rheumatoid arthritis (RA) and 24 healthy controls. T(reg) phenotypic markers, including CD39 expression, were studied by flow cytometry. Varying numbers of sorted T(regs) cells were co-cultured with responder T (T(resp)) cells, with proliferation assessed by (3)H-thymidine incorporation. The proportion of T(regs) as defined by Foxp3(+) CD25(+high) CD127(-/low) was similar in lupus and control populations. CD39-expressing T(regs) comprised 37±13% of the T(reg) population in healthy controls and 36±21% in lupus subjects using nonsteroidal immunosuppressants to control active disease, but was nearly absent in five of six lupus subjects with minimally active disease. In contrast to healthy controls and lupus subjects without the CD39 defect, in SLE subjects with the CD39 defect, adenosine-dependent T(reg)-mediated suppression was nearly absent. These results suggest that functional defects in T(regs), rather than reduced T(reg) numbers, are important for the loss of peripheral tolerance in lupus. Presentation of this defect may serve as a biomarker for untreated disease.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21763644      PMCID: PMC3168146          DOI: 10.1016/j.cellimm.2011.06.010

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  36 in total

1.  Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific.

Authors:  A M Thornton; E M Shevach
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

2.  Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage.

Authors:  A Ohta; M Sitkovsky
Journal:  Nature       Date:  2001 Dec 20-27       Impact factor: 49.962

3.  High gradient magnetic cell separation with MACS.

Authors:  S Miltenyi; W Müller; W Weichel; A Radbruch
Journal:  Cytometry       Date:  1990

4.  Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus.

Authors:  Xavier Valencia; Cheryl Yarboro; Gabor Illei; Peter E Lipsky
Journal:  J Immunol       Date:  2007-02-15       Impact factor: 5.422

5.  Protein kinase A RI beta subunit deficiency in lupus T lymphocytes: bypassing a block in RI beta translation reconstitutes protein kinase A activity and augments IL-2 production.

Authors:  I U Khan; D Laxminarayana; G M Kammer
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

6.  [3H]xanthine amine congener of 1,3-dipropyl-8-phenylxanthine: an antagonist radioligand for adenosine receptors.

Authors:  K A Jacobson; D Ukena; K L Kirk; J W Daly
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

7.  Enhancement of the impaired autologous mixed leukocyte reaction in patients with systemic lupus erythematosus.

Authors:  M K Crow
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

8.  T helper cell dysfunction in systemic lupus erythematosus (SLE): relation to disease activity.

Authors:  B L Bermas; M Petri; D Goldman; B Mittleman; M W Miller; N I Stocks; C S Via; G M Shearer
Journal:  J Clin Immunol       Date:  1994-05       Impact factor: 8.317

9.  T cell-antigen-presenting cell interactions in human systemic lupus erythematosus. Evidence for heterogeneous expression of multiple defects.

Authors:  C S Via; G C Tsokos; B Bermas; M Clerici; G M Shearer
Journal:  J Immunol       Date:  1993-10-01       Impact factor: 5.422

10.  Adenosine acts as an endogenous modulator of IL-2-dependent proliferation of cytotoxic T lymphocytes.

Authors:  M A Antonysamy; E J Moticka; V Ramkumar
Journal:  J Immunol       Date:  1995-09-15       Impact factor: 5.422

View more
  14 in total

Review 1.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

2.  Ankylosing spondylitis monocyte-derived macrophages express increased level of A2A adenosine receptor and decreased level of ectonucleoside triphosphate diphosphohydrolase-1 (CD39), A1 and A2B adenosine receptors.

Authors:  Maryam Akhtari; Seyed Jalal Zargar; Mahdi Mahmoudi; Mahdi Vojdanian; Alireza Rezaeimanesh; Ahmadreza Jamshidi
Journal:  Clin Rheumatol       Date:  2018-03-09       Impact factor: 2.980

Review 3.  The impact of the gut microbiome on extra-intestinal autoimmune diseases.

Authors:  Eiji Miyauchi; Chikako Shimokawa; Alex Steimle; Mahesh S Desai; Hiroshi Ohno
Journal:  Nat Rev Immunol       Date:  2022-05-09       Impact factor: 53.106

Review 4.  Promises and paradoxes of regulatory T cells in inflammatory bowel disease.

Authors:  James D Lord
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

5.  Autoimmune Reactivity in Graft Injury: Player or Bystander?

Authors:  Vrushali V Agashe; William J Burlingham
Journal:  Curr Transplant Rep       Date:  2015-07-07

6.  Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis.

Authors:  J S Yi; A Guidon; S Sparks; R Osborne; V C Juel; J M Massey; D B Sanders; K J Weinhold; J T Guptill
Journal:  J Autoimmun       Date:  2013-12-28       Impact factor: 7.094

Review 7.  Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers.

Authors:  Philip M Brown; Arthur G Pratt; John D Isaacs
Journal:  Nat Rev Rheumatol       Date:  2016-10-27       Impact factor: 20.543

8.  Effect of Uncaria tomentosa extract on purinergic enzyme activities in lymphocytes of rats submitted to experimental adjuvant arthritis model.

Authors:  Lívia G Castilhos; João F P Rezer; Jader B Ruchel; Maria Luiza Thorstenberg; Jeandre A dos S Jaques; Josiane B Schlemmer; Pedro H Doleski; Mateus F Rossato; Mariane A da Silva; Emerson André Casalli; Ritiel Corrêa da Cruz; Juliano Ferreira; Margareth L Athayde; Jamile F Gonçalves; Daniela B R Leal
Journal:  BMC Complement Altern Med       Date:  2015-06-20       Impact factor: 3.659

9.  Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry.

Authors:  Saskia J A M Santegoets; Eveline M Dijkgraaf; Alessandra Battaglia; Philipp Beckhove; Cedrik M Britten; Awen Gallimore; Andrew Godkin; Cecile Gouttefangeas; Tanja D de Gruijl; Hans J P M Koenen; Alexander Scheffold; Ethan M Shevach; Janet Staats; Kjetil Taskén; Theresa L Whiteside; Judith R Kroep; Marij J P Welters; Sjoerd H van der Burg
Journal:  Cancer Immunol Immunother       Date:  2015-06-28       Impact factor: 6.968

Review 10.  Ectonucleotidases in tumor cells and tumor-associated immune cells: an overview.

Authors:  Letícia Scussel Bergamin; Elizandra Braganhol; Rafael Fernandes Zanin; Maria Isabel Albano Edelweiss; Ana Maria Oliveira Battastini
Journal:  J Biomed Biotechnol       Date:  2012-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.